NASDAQ · NWBO
Healthcare · Biotechnology
$0.17
Up+$0.00 (+2.55%)
Updated Sep 15, 2026, 6:24 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NWBO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning NWBO.
NWBO research
Company profile and research snapshot.
NORTHWEST BIOTHRPUTCS INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Jul 8, 2026
NWBO stock update: Follow Northwest Bioâs cancer immunotherapy pipeline and finances. Click here to read my most recent analysis of NWBO stock.
Yahoo · Jul 2, 2026
Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be making a scientific presentation entitled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses" at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). The presentation is scheduled for Friday, July 3,
Finnhub · May 15, 2026
BETHESDA, Md. — BETHESDA, Md. — Northwest Biotherapeutics Inc. on Friday reported a loss of $3.1 million in its first quarter. On a per-share basis, the Bethesda, Maryland-based company said...
Finnhub · Apr 30, 2026
BETHESDA, Md., April 30, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. , a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NWBO.
